SURESAVE TM SELF-EXPANDABLE NITINOL STENT AND PRECISION TM DELIVERY CATHETER-SS06120060

K060557 · Idev Technologies, Inc. · FGE · Aug 15, 2006 · Gastroenterology, Urology

Device Facts

Record IDK060557
Device NameSURESAVE TM SELF-EXPANDABLE NITINOL STENT AND PRECISION TM DELIVERY CATHETER-SS06120060
ApplicantIdev Technologies, Inc.
Product CodeFGE · Gastroenterology, Urology
Decision DateAug 15, 2006
DecisionSESU
Submission TypeTraditional
Regulation21 CFR 876.5010
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The SureSave™ Self-Expandable Biliary Nitinol Stent and Precision™ Stent Delivery Catheter is indicated for palliative treatment of biliary strictures produced by malignant neoplasms.

Device Story

SureSave stent is a self-expanding, braided metallic stent made of biomedical superalloy wire; delivered via Precision catheter system. Catheter features inner/outer tubes; outer tube constrains stent until deployment; inner tube contains lumen for 0.018" guidewire. Radiopaque marker bands on catheter facilitate imaging during placement. Used by physicians in clinical settings to treat biliary strictures. Stent provides radial force to maintain patency in malignant biliary obstructions, offering palliative relief to patients.

Clinical Evidence

Bench testing only.

Technological Characteristics

Stent: braided tubular mesh, biomedical superalloy wire. Delivery system: dual-catheter (inner/outer) design, 0.018" guidewire compatibility, radiopaque marker bands. Self-expanding mechanism. Non-software device.

Indications for Use

Indicated for palliative treatment of biliary strictures caused by malignant neoplasms in the biliary tree.

Regulatory Classification

Identification

A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.

Special Controls

*Classification.* Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ IDev® Technologies, Inc. SureSave™ Self-Expandable Biliary Nitinol Stent and Precision™ Stent Delivery Catheter 510(k) Notification ## AUG 1 5 2006 #### SureSave™M ## Self-Expandable Biliary Nitinol Stent and Precision™ Stent Delivery Catheter 510(k) Summary | Submitter: | IDev Technologies, Inc.<br>1120 NASA Road One, Suite 600<br>Houston, Texas 77058 | |-------------------|-----------------------------------------------------------------------------------------------------------------------------------------| | Contact Person: | Timothy R. Placek<br>Vice President, Regulatory Affairs, Clinical Affairs and Quality<br>(281) 333-1998 (Phone)<br>(281) 333-4008 (Fax) | | Date Prepared: | March 1, 2006 | | Trade Name: | SureSaveTM Self-Expandable Biliary Nitinol Stent and PrecisionTM Stent<br>Delivery Catheter | | Product Code: | FGE | | Predicate Device: | Protege® GPSTM Self-Expanding Nitinol Stent - Biliary (K051379)<br>SMARTTM ControlTM Nitinol Stent Transhepatic - Biliary (K032457) | #### Device Description: The SureSave™ Self-Expandable Biliary Nitinol Stent and Precision™ Stent Delivery Catheter is comprised of two components; the implantable SureSave™ metallic stent and the Precision™ delivery system. The stent, provided pre-mounted on the delivery system, is a woven wire is constructed from a biomedical superalloy wire, braided in a tubular mesh configuration. The design configuration results in a stent that is flexible, compliant, self-expanding and can withstand strong radial force. The delivery system consists of an inner and outer catheter. The exterior catheter serves to constrain the stent until retracted during delivery. Radiopaque marker bands situated on the interior and exterior tubes aid in imaging during deployment. The inner catheter contains a central lumen which will accommodate a 0.018" guidewire. #### Intended Use: The SureSave™ Self-Expandable Biliary Nitinol Stent and Precision™ Stent Delivery Catheter is indicated for palliative treatment of biliary strictures produced by malignant neoplasms. #### Technological Characteristics Compared to Predicate The SureSave™ Self-Expandable Biliary Nitinol Stent and Precision™ Stent Delivery Catheter is substantially equivalent to the predicate devices. The equivalence was confirmed through preclinical testing. {1}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized depiction of an eagle with three stripes forming its body and wings. The logo is encircled by the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA". #### Public Health Service # AUG 1 5 2006 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Timothy R. Placek VP of Regulatory Affairs, Clinical Affairs and Quality Systems Official Correspondent IDev Technologies, Inc. 1120 NASA Road One, Suite 600 HOUSTON TX 77058 Re: K060557 Trade/Device Name: SureSave" Self-Expandable Biliary Nitinol Stent and Precision™ Stent Delivery Catheter Regulation Number: 21 CFR §876.5010 Regulation Name: Biliary catheter and accessories Regulatory Class: II Product Code: 78 FGE Dated: July 7, 2006 Received: July 10, 2006 Dear Mr. Placek: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling: The safety and effectiveness of this device for use in the vascular system have not been established. Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print. {2}------------------------------------------------ ### Page 2 - Mr. Timothy Placek Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours, Donna-Bea Tillman, Ph.D., M.P.A. Director Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ # Indications for Use 510(k) Number (if known): K060557 SureSave " Self-Expandable Biliary Nitinol Stent and Precision™ Stent Device Name: Delivery Catheter FDA Indications For Use: The SureSave™ Self-Expandable Biliary Nitinol Stent and Precision" Stent Delivery Catheter is intended for use in the palliation of malignant neoplasms in the biliary tree. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) David G. Seymour (Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number__ KO6055 Page 1 of 1 Page 4 - Mr. Timothy Placek
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...